What is Pegfilgrastim-cbqv Subcutaneous
Pegfilgrastim-cbqv subcutaneous is a medication used to decrease the risk of infection in people receiving chemotherapy that harms white blood cells. Pegfilgrastim-cbqv subcutaneous is a man-made form of a protein that helps the body make white blood cells.
Benefits of Pegfilgrastim-cbqv Subcutaneous
and Its Uses.
Pegfilgrastim-cbqv, also known as Neulasta, is a medication used to prevent infection in people undergoing chemotherapy. Chemotherapy can weaken the body’s immune system, making it more susceptible to infection. Pegfilgrastim-cbqv is a man-made form of the human protein granulocyte colony-stimulating factor (G-CSF), which helps the body produce white blood cells.
Pegfilgrastim-cbqv is given as a subcutaneous (under the skin) injection. It is available as a powder that must be mixed with a liquid before use. The medication comes in a prefilled syringe or a vial that you must mix with a diluent before use.
Pegfilgrastim-cbqv is used to prevent infection in people undergoing chemotherapy.
Chemotherapy can weaken the body’s immune system, making it more susceptible to infection. Pegfilgrastim-
Side Effects and Dosage of Pegfilgrastim-cbqv Subcutaneous
Pegfilgrastim-cbqv is a recombinant human granulocyte colony-stimulating factor (G-CSF) indicated to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. Pegfilgrastim-cbqv is supplied as a subcutaneous injection in a prefilled syringe.
The recommended dose of pegfilgrastim-cbqv is 6 mg/kg/day as a subcutaneous injection, administered once daily.
The safety and efficacy of pegfilgrastim-cbqv have not been established in patients with myeloid malignancies.
Pegfilgrastim-cbqv is contraindicated in patients with hypersensitivity to pegfilgrastim-cbqv or filgrastim.